Avant Technologies appoints Kenneth L. Waggoner as CEO with $720K salary in shares

AVAI BIO, INC.

Kenneth L. Waggoner named CEO effective July 10, 2024; 1-year term renewable automatically.
Base salary $720k annual paid in common shares quarterly at 20-day VWAP; increases to $1.44M upon national exchange listing.
Additional bonus of 10% of net equity financing raised if deemed sufficient by Board.
Former interim CEO Hisey reappointed as CFO; Racius reappointed as COO while remaining Director and Treasurer.
CEO has 45 years experience including senior roles at Chevron and PharmaCyte Biotech.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Hisey

Chief Financial Officer

AVAI · AVAI BIO, INC.

Effective: 2024-07-10
Filed: July 15, 2024, 7:59 PM ET

Mr. Hisey, the current interim CEO of the Company, was reappointed as Chief Financial Officer (the “CFO”).

Role change

Racius

Chief Operating Officer

AVAI · AVAI BIO, INC.

Effective: 2024-07-10
Filed: July 15, 2024, 7:59 PM ET

Mr. Racius, the current CFO, Director, and Treasurer, was reappointed as the Company's Chief Operating Officer (the “COO”) while continuing his roles as Director and Treasurer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Hisey was appointed as Chief Financial Officer at AVAI BIO, INC..

Action: reappointed
Role: Chief Financial Officer

Exact text from the filing

Mr. Hisey, the current interim CEO of the Company, was reappointed as Chief Financial Officer (the “CFO”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Racius was appointed as Chief Operating Officer at AVAI BIO, INC..

Action: reappointed
Role: Chief Operating Officer

Exact text from the filing

Mr. Racius, the current CFO, Director, and Treasurer, was reappointed as the Company's Chief Operating Officer (the “COO”) while continuing his roles as Director and Treasurer.

View on SEC.gov

AVAI BIO, INC. filing history →

Source: SEC EDGAR

accession 0001740797-24-000033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.